|Dear Seed Investor,
2017 was a major year for Marijuana Stocks, and 2018 is shaping up to be even bigger.
It's been a year of meteoric growth for multiple Cannabis stocks, with the Cannabis Stock Index up 91% YTD.
Looking forward to 2018, California, the largest market in the US, is preparing for recreational legalization in January 2018.
Canada is scheduled for full recreational legalization in July 2018, with multiple Canadian provinces already outlining their plans for legalization.
Mergers and acquisitions like the deal between Constellation Brands and Canopy have solidified and legitimized the space.
This all contributes to an overall bullish outlook heading into 2018.
Here are just a few of the hightlights from 2017:
Canopy Growth Corporation (TSX: WEED) (OTCQB: TWMJF) announced a major deal with with the leading total beverage alcohol supplier in the United States, Constellation Brands (NYSE: STZ and STZ.B).
This deal sees Constellation invest $245 Million in Canopy for ~10% of the company, in a deal that is seen as a "potential game changer for rallying pot stocks" and marks the first major investment in the marijuana space by big alcohol.
Canopy is the largest cannabis company in the world, and their stock has risen by 367% this year!
Aurora Cannabis Inc. (TSX: ACB) (OTCQB: ACBFF) announced a takeover bid to purchase all of the issued and outstanding common shares of CanniMed Therapeutics Inc. (TSX: CMED) (OTCQB: CMMDF).
Although the takeover has not been approved yet and is still being decided in the courts, this was a major story in 2017.
Aurora has seen stock growth of ~373% this year!
ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) is seeing a gain of ~70% over the past 3 months, including a year high of $1.81 for a ~126% gain this year!
They solidified their funding with a major deal with Cannabis Wheaton, continued with their robust expansion plans and brought on expertise with the addition of Barry Fishman as CEO.
InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF) also had a monster year, showing gains of ~160% in the last 3 months alone, and over ~563% year over year!
They increased shareholder value on the strength of groundbreaking research on their proprietary Biosynthesis program. This culminated with the recent news of being added to the Horizons Marijuana Life Sciences Index ETF on December 15, 2017
MedReleaf Corp. (TSX:LEAF) (OTCQB: MEDFF) announced that it entered into an agreement to become a medical cannabis supplier to Shoppers Drug Mart, Canada's largest retail pharmacy chain, pending Health Canada's approval of Shoppers Drug Mart's application to be a licensed producer.
MedReleaf has seen a ~206% gain this year on the strength of this news.
All in all it's been a very successful year for Marijuana stocks in general, including our top stock picks.
Enjoy the rest of your holidays and we look forward to High‘er Profits for the New Year.
The Seed Investor